
alpha investor
110 posts

alpha investor
@ErezIdan
MBA | Investor | Navigating global markets with strategic insight.















Kaizen Portfolio update of March. My portfolio was up 6.9% this month. My top 4 positions outperformed the rest of my porftolio. $PL reported great Q4 results and are up 45% this month. $PLTR is up 7% and $RKLB 2%. $AMPX also reported excellent results and is surfing on a growing drone wave, they are up 45% this month. I initiated 4 new positions: $OUST, $POET, $MRVL and SK Hynix. I'm up 15% on Marvell, the other positions are flat. I also bought some extra shares of $HIMS. I think they are ideally positioned to catch the GLP-1 wave and I'm happy to keep DCA'ing into the company. On the other end of the spectrum $TMDX dropped 25% this month. $HOOD, $FLNC, and $IREN dropped around 7%. I'll see what tomorrow brings as Trump keeps controlling the markets. I'm at 20% cash at the moment, will be looking to get this down to 10% this month. I'm also looking to get more concentration in my portfolio. I'm lookin gto add 1 new position and will probably sell 5 to 6 positions. This shold bring my total holdings down from 16 to 11. Will keep you posted.









I continue to think $HROW is one of the most undervalued / mispriced growth stocks in the entire market. $HROW is down -33% in the past couple weeks, now trading at 15x NTM ev/ebitda... despite management saying CY2026 revenues will be up +32% YoY (midpoint of guidance) and ebitda will be up +45% YoY (midpoint of guidance). Management said multiple times in the shareholder letter and the earnings call that this guidance is conservative. If you are interested in $HROW or already have a position, I strongly encourage you to listen to the CEO from yesterday's presentation at the Leerink Healthcare conference... event.summitcast.com/view/mT9poctHD… During this presentation, Mark (founder & CEO) said their current guidance is "base case" for CY2026. I used to tell my subs that I'm always looking for breadcrumbs... Mark dropped some big ones during this presentation. I'm listening to it for the second time right now. Not only is $HROW expecting approval next month on a new indication, but he said they're presenting data in July for Izeeho that he thinks can 4x their market share. Then he said G-Melt could be in market within the next 18-24 months and has the potential to become their biggest revenue product ever. CEO also said they are doubling the size of their sales teams over the next 3-6 months because the ROI of having better coverage in more markets is just too obvious. Mark continues to say they can get to $250M in quarterly revenues by CY2027 Q4, which implies approx $1B in CY2028 revenues. Right now $HROW is expecting CY2026 ebitda margins of 26%, if anyone knows biopharma companies and margins... as they scale revenues from here, those margins will get much better. It's very possible $HROW has 35-40% ebitda margins in CY2028 at which point they could be generating $350-400M of ebitda... right now the current enterprise value is $1.5B... so it's possible that $HROW is currently trading at just 4x CY2028 ev/ebitda not including all the cash they'll generate over the next few years. I honestly think $HROW has the potential to be a 5-bagger over the next 3 years. NFA. DYOR. *We own $HROW at @FirstWaveFund; as of this morning it's now a top 8 position.






